News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
INDUSTRY
INDUSTRY
Marketing Approval
Innovative Drug
Generic Drug
Biological Product
Cancer
Rare Disease
Drug Registration
New Drug
Respiratory Disease
Monthly Report: New Drug Approvals in China | October 2023
In Oct 2023, China NMPA approved 15 new drugs, among which 12 are chemical drugs and 3 are biological products: 1. BMS’ Deucravacitinib Tablets (SOTYKTU); 2. Pfizer’s Ritlecitinib Tosylate Capsules (LITFULO); 3. Janssen-Cilag International’s Rilpivirine Injection; 4. Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch; 5. Abbvie’s Upadacitinib Sustained-release Tablets (RINVOQ)...
Nov 06, 2023
INDUSTRY
Marketing Approval
Priority Review
Innovative Drug
Generic Drug
Biological Product
Cancer
Diabetes
Drug Registration
New Drug
Monthly Report: New Drug Approvals in China | June 2023
In June 2023, China NMPA approved 33 new drugs, among which 26 are chemical drugs while 7 are biological products.
Jul 07, 2023
Most Popular
- [Updated] Pharma Licensing Deals Involving Chinese Companies in 2023
- [Updated] Top 10 CROs With the Highest Revenues in 2023
- Decoding China's Good Pharmacovigilance Practices (GVP)
- 2023 China CDE Drug Evaluation Report
- [Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China